HDT Bio Corp And Gennova Complete Phase 1 Trial Of COVID-19 RNA Vaccine In India

[email protected]26 Oct, 2021News

HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, announced today that its development partner in India, Gennova Biopharmaceuticals, successfully completed a Phase 1 trial of its COVID-19 RNA vaccine candidate HGCO19 and Indian regulatory authorities have approved the start of pivotal Phase 2/3 trials. This vaccine uses HDT Bio?s proprietary LIONTM RNA-delivery technology.